BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia

Inclusion Criteria: * Patients with Philadelphia chromosome positive, chronic, accelerated or blast phase BML or ALL. * Patients must have primary or acquired hematologic resistance to imatinib mesylate or have intolerance of imatinib mesylate. * Men and women, 14 years of age or older. * Adequate renal function. * Adequate hepatic function. * Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least 1 month before and at least 3 months after the study in such a manner that the risk of pregnancy is minimized. Exclusion Criteria: * Patients who are eligible and willing to undergo transplantation during the screening period. * Women who are pregnant or breastfeeding. * A serious uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy. * Uncontrolled or significant cardiovascular disease. * Medications that increase bleeding risk. * Medications that change heart rhythms. * Dementia or altered mental status that would prohibit the understanding of rendering of informed consent. * History of significant bleeding disorder or unrelated to CML. * Evidence of organ dysfunction or digestive dysfunction that would prevent administration of study therapy. * Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.